Array BioPharma

+$0.00 (+0.0%)
Closing price February 19, 2020

Top Analyst Upgrades and Downgrades: Array Bio, Bank of America, Oracle, Pinterest, RingCentral, Snap, SunPower, Twilio, Xilinx and More

Stocks were indicated to open higher on Tuesday after a small gain in the Dow and S&P 500 on Monday. It may be the summer, but investors need to be ...
Read Full Story »

How Much Is Pfizer Overpaying For Array Bio?

Array BioPharma Inc. (NASDAQ: ARRY) shares shot up on Monday after the firm announced that it would be acquired by Pfizer Inc. (NYSE: PFE) in an all cash transaction. The ...
Read Full Story »

4 Price Momentum Stocks Hedge Funds Love Could Be Big Summer Winners

We have noted that hedge fund performance over the past couple of years, especially by some of the bigger funds, has trailed the overall market performance. Part of the problem ...
Read Full Story »

Why 6 Top Biotech Stocks Could Beat Wall Street Q4 Estimates

If most investors thought their portfolios took a beating during the final quarter of 2018, it was a good thing they were not all-in on the biotechnology segment. The VanEck ...
Read Full Story »

Analysts Have 12 Top Biotech Picks for Big Upside in 2018

After a horrible 2015 and 2016, the biotechnology industry finally came back to life in 2017, shrugging off many of the issues that have clouded the waters, especially during the ...
Read Full Story »

4 Red-Hot Tech and Biotech Stocks to Buy With Up to 100% Upside Potential

For investors who have watched the staggering moves in bitcoin and somehow feel that they missed the bus, they were reminded last week when the cryptocurrency dropped back almost 35% ...
Read Full Story »

Array BioPharma Slides on Secondary Offering

Array BioPharma Inc. (NASDAQ: ARRY) saw its shares turn negative early on Thursday after the firm announced a secondary offering. The company offered no pricing details, but it does value ...
Read Full Story »

Top Analyst Upgrades and Downgrades: GrubHub, Kroger, Newell Brands, Seagate, Snap, Sony, WEX, FireEye and More

Stocks were indicated to open sharply higher on Monday, with Hurricane Irma having drifted westward in Florida just enough to cause far less financial damage than what had been expected on Thursday and ...
Read Full Story »

Array BioPharma’s New FDA Submissions Enough to Excite Investors?

Array BioPharma Inc. (NASDAQ: ARRY) saw its shares were up handily in Wednesday's premarket after the firm announced a critical submission to the U.S. Food and Drug Administration (FDA). Specifically, ...
Read Full Story »

JPMorgan’s Favorite Biotechs to Buy With Massive Upside Potential

After a couple of down years in which the shrill political rhetoric over drug prices kept a pall over the industry, the biotechs are showing some signs of life. In ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Alcoa, Altria, Ford, GoPro, NVIDIA, International Paper, Transocean and Many More

Stocks have seen big swings in a mixed week. There was a dovish Fed meeting that gave no directional bias on rates, and now we have a much stronger than ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Amex, Barclays, DuPont, NetApp, Plains All American, Viacom, Disney and More

Stocks broke through the DJIA 20,000 and S&P 2,300 barriers last week, but stocks were indicated lower on Monday. Even with this bull market almost eight years old, investors still want ...
Read Full Story »

7 Analyst Stocks Under $10 for Massive Upside Projections

The week of November 4 was dominated by investors selling stocks. Despite high valuations, a Federal Reserve that wants to raise interest rates, election uncertainty and even declining earnings, the ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Agrium, Array BioPharma, Encana, GoPro, 3D Systems and More

Stocks were looking for direction ahead of the unemployment and payrolls report, but this is after eight days of consecutive selling. For more than five years investors have used a different ...
Read Full Story »

Top 6 Biopharma Gainers of the Past Week

Over the past week, a few biotech companies made absolutely massive runs. The health care sector has been under fire from Washington over the past year, but it seems that ...
Read Full Story »